Acquired von Willebrand syndrome is a highly heterogeneous bleeding disorder, that usually displays mild to moderate hemorrhagic symptoms that may at times be severe too. Many a time the severity increases post-surgery. AvWS is considered a rare disorder, however, the actual prevalence is not as rare. In case the laboratory findings diagnose vWD in a patient with no family history, AvWS-associated conditions are usually explored. The acquired von Willebrand disease treatment market is anticipated to grow, at a CAGR of 5.86% during the forecast period of 2024 to 2032.
Browse For Report at https://www.acutemarketreports.com/report/acquired-von-willebrand-syndrome-avws-treatment-market
High cost of treatment is one of the most significant challenges for patients with VWD. The cost of investments for drug development is high due as it is a rare disorder with fewer patients. Additionally, the distinctive treatment approach for this disease makes it expensive. The recombinant therapy is comparatively expensive. Therefore, cost remains as significant challenge impacting the growth of the market.
Replacement therapies segment is expected to grow at the fastest pace, due to its effectiveness and sustained results in emergency situations. Additionally, a focus on innovative products in this segment is expected to raise the growth rate of replacement therapies over the forecast period of 2024 to 2032.
In the year 2023, Hospitals remained as the key healthcare setting due to the availability of broad range of therapeutic options. Additionally, the availability of registered medical practitioners along with reimbursement policies make hospitals the most preferable healthcare setting for the management and treatment of hemophilia. Clinics are expected to grow fastest during the forecast period as they are cost-effective and less complex in comparison to hospitals.
North America was observed as the largest market for AvWS treatment in 2023. North America dominated the market due to its aging population, supportive government policies, high awareness associated with hemophilia and types in people, and developed healthcare infrastructure. Asia Pacific was observed as an attractive market for AvWS treatment due to its emerging healthcare infrastructure, high disposable income, transforming government policies specific to orphan diseases diagnosis and treatment, and rising public awareness associated with healthcare insurance and disease diagnosis. The key players in the acquired AvWS treatment market are Novo Nordisk A/S, Genentech, Inc., F. Hoffman-La Roche AG, Sanofi SA, and others.
KEY MARKET MOVEMENTS
